Diconbio

Diconbio is a South Korean biotechnology company focused on the development of next-generation metabolic therapies. The company specializes in creating multi-agonist small molecules that target key metabolic receptors, including GLP-1, GCG, and GIP, to address complex conditions such as obesity and type 2 diabetes. By leveraging its expertise in medicinal chemistry, Diconbio aims to provide oral alternatives to existing injectable peptide therapies, potentially improving patient compliance and therapeutic outcomes. The company's lead programs are currently in the pre-clinical stage, with a focus on optimizing potency and safety profiles for clinical advancement.